Aurothioglucose
drugOn this page
Also known as AureotanAurumineAuthronBrenolGlysanol bNSC-759601OronolSolganal bSID144205102
Summary
Aurothioglucose (CHEMBL1697725) is an approved small molecule (ATC M01CB04); indicated across 1 condition including rheumatic disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: M01CB04
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1697725 |
| Name | Aurothioglucose |
| Type | Small molecule |
| Max phase | 4 |
| ATC | M01CB04 |
Also known as: Aureotan, Aurothioglucose, Aurumine, Authron, Brenol, Glysanol b, NSC-759601, Oronol, Solganal b, SID144205102, AUROTHIOGLUCOSE, aurothioglucose
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| 5-HT3A | Antagonist | 10.49 |
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: 3’,5’-cyclic-AMP phosphodiesterase 4A, Vascular endothelial growth factor receptor 2, Replicase polyprotein 1ab, Sulfide:quinone oxidoreductase, mitochondrial, Replicase polyprotein 1ab.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| SQOR | 6.03 | IC50 | 925 | nM | CHEMBL_ACT_19326682 |
| SQOR | 6.03 | IC50 | 924.7 | nM | CHEMBL_ACT_19326683 |
| KDR | 5.77 | AC50 | 1716 | nM | CHEMBL_ACT_25168616 |
| P0DTD1 | 5.76 | IC50 | 1740 | nM | CHEMBL_ACT_19964250 |
| PDE4A | 5.23 | AC50 | 5889 | nM | CHEMBL_ACT_25207616 |
| K9N7C7 | 5 | IC50 | 10000 | nM | CHEMBL_ACT_19964340 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| rheumatic disorder | 4 | MONDO:0005554 | EFO:0005755 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: rheumatic disorder